Englander Institute for Precision Medicine

Publications

Found 22 results
Author Title Type [ Year(Asc)]
Filters: Author is Bhinder, Bhavneet  [Clear All Filters]
2024
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2024.  Author Correction: Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 15(1):225.
Noch EK, Palma L, Yim I, Bullen N, Barnett D, Walsh A, Bhinder B, Benedetti E, Krumsiek J, Gurvitch J et al..  2024.  Cysteine induces mitochondrial reductive stress in glioblastoma through hydrogen peroxide production.. Proc Natl Acad Sci U S A. 121(8):e2317343121.
Ohara K, Rendeiro AFigueiredo, Bhinder B, Eng KWha, Ravichandran H, Nguyen D, Pisapia D, Vosoughi A, Fernandez E, Shohdy KS et al..  2024.  The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis.. Nat Commun. 15(1):2009.
Altorki NK, Bhinder B, Borczuk AC, Elemento O, Mittal V, McGraw TE.  2024.  A signature of enhanced proliferation associated with response and survival to anti-PD-L1 therapy in early-stage non-small cell lung cancer.. Cell Rep Med. :101438.
2023
Liu W, Newhall KP, Khani F, Barlow LM, Nguyen D, Gu L, Eng K, Bhinder B, Uppal M, Récapet C et al..  2023.  The Cytidine Deaminase APOBEC3G Contributes to Cancer Mutagenesis and Clonal Evolution in Bladder Cancer.. Cancer Res. 83(4):506-520.
Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KWha, Uppal M, He F et al..  2023.  Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.. Blood Cancer Discov. 4(3):208-227.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.
Crowley MJP, Bhinder B, Markowitz GJ, Martin M, Verma A, Sandoval TA, Chae C-S, Yomtoubian S, Hu Y, Chopra S et al..  2023.  Tumor-intrinsic IRE1α signaling controls protective immunity in lung cancer.. Nat Commun. 14(1):120.
2022
Fontugne J, Cai PY, Alnajar H, Bhinder B, Park K, Ye H, Beg S, Sailer V, Siddiqui J, Blattner-Johnson M et al..  2022.  Collision tumors revealed by prospectively assessing subtype-defining molecular alterations in 904 individual prostate cancer foci.. JCI Insight. 7(4)
Altorki NK, Borczuk AC, Harrison S, Groner LK, Bhinder B, Mittal V, Elemento O, McGraw TE.  2022.  Global evolution of the tumor microenvironment associated with progression from preinvasive invasive to invasive human lung adenocarcinoma.. Cell Rep. 39(1):110639.
2021
Bhinder B, Gilvary C, Madhukar NS, Elemento O.  2021.  Artificial Intelligence in Cancer Research and Precision Medicine.. Cancer Discov. 11(4):900-915.
Rivas MA, Durmaz C, Kloetgen A, Chin CR, Chen Z, Bhinder B, Koren A, Viny AD, Scharer CD, Boss JM et al..  2021.  Cohesin Core Complex Gene Dosage Contributes to Germinal Center Derived Lymphoma Phenotypes and Outcomes.. Front Immunol. 12:688493.
Shah Y, Verma A, Marderstein AR, White J, Bhinder B, J Medina SGarcia, Elemento O.  2021.  Pan-cancer analysis reveals molecular patterns associated with age.. Cell Rep. 37(10):110100.
Rivas MA, Meydan C, Chin CR, Challman MF, Kim D, Bhinder B, Kloetgen A, Viny AD, Teater MR, McNally DR et al..  2021.  Smc3 dosage regulates B cell transit through germinal centers and restricts their malignant transformation.. Nat Immunol. 22(2):240-253.
2020
Vosoughi A, Zhang T, Shohdy KS, Vlachostergios PJ, Wilkes DC, Bhinder B, Tagawa ST, Nanus DM, Molina AM, Beltran H et al..  2020.  Common germline-somatic variant interactions in advanced urothelial cancer.. Nat Commun. 11(1):6195.
Bhinder B, Elemento O.  2020.  Computational methods in tumor immunology.. Methods Enzymol. 636:209-259.
Marderstein AR, Uppal M, Verma A, Bhinder B, Tayyebi Z, Mezey J, Clark AG, Elemento O.  2020.  Demographic and genetic factors influence the abundance of infiltrating immune cells in human tissues.. Nat Commun. 11(1):2213.
Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.
2019
Boehm KMichael, Bhinder B, Raja VJoseph, Dephoure N, Elemento O.  2019.  Predicting peptide presentation by major histocompatibility complex class I: an improved machine learning approach to the immunopeptidome.. BMC Bioinformatics. 20(1):7.
Robinson BD, Vlachostergios PJ, Bhinder B, Liu W, Li K, Moss TJ, Bareja R, Park K, Tavassoli P, Cyrta J et al..  2019.  Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.. Nat Commun. 10(1):2977.
2018
Markowitz GJ, Havel LS, Crowley MJp, Ban Y, Lee SB, Thalappillil JS, Narula N, Bhinder B, Elemento O, Wong STc et al..  2018.  Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival.. JCI Insight. 3(13)
2016
Rennert H, Eng K, Zhang T, Tan A, Xiang J, Romanel A, Kim R, Tam W, Liu Y-C, Bhinder B et al..  2016.  Development and validation of a whole-exome sequencing test for simultaneous detection of point mutations, indels and copy-number alterations for precision cancer care.. NPJ Genom Med. 1:16019-.